Pharmaceuticals

PULIKE

PULIKE released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 266.87 M, actual EPS CNY 0.0806

PULIKE released FY2025 Annual Earnings on April 28 After-Market (BJT), Actual Revenue CNY 1.09 B (Forecast CNY 1.185 B), Actual EPS CNY 0.54 (Forecast CNY 0.53)

PULIKE released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 249.24 M, actual EPS CNY 0.12

PULIKE FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

PULIKE to Release FY2025 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 1.185 B, EPS CNY 0.53

PULIKE released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 263.58 M, actual EPS CNY 0.1199

PULIKE released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 823.01 M, actual EPS CNY 0.4593

PULIKE to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

PULIKE released FY2025 Semi-Annual earnings on August 28 After-Market (BJT), actual revenue CNY 559.43 M, actual EPS CNY 0.34

PULIKE released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 280.81 M, actual EPS CNY 0.1793

PULIKE to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Pouleika Announces 44.70%-64.98% YoY Net Profit Growth for H1 2025

Poultry Company Subsidiary Obtains Registration Certificate for New Veterinary Drug

Huake Actively Researching Pet Ecology Related Businesses

Pulike Obtains New Veterinary Drug Registration Certificate for Preventing Infectious Synovitis in Chickens

Pleiku Investor Asks About Diversification Strategy

Pulike Updates on ASF Vaccine Development and Stock Repurchase

Poultry Company Kelco Obtains New Veterinary Drug Registration Certificate for Fluralaner Solution

Pulike faces short-term business pressures, with growth driven by poultry vaccines and pharmaceuticals

Pulike's Net Profit Soars 93.75% in Q1 2025

603392

600201

603566

300142

300119

688185

06185

Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

Zhitong

Wantai Biological

JINYU

WALVAX

RINGPU

CanSinoBIO

CANSINOBIO

Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

HuaChuang Securities released a research report indicating that since 2025, the prices of veterinary raw materials have stabilized and rebounded, especially for macrolide products, where prices and profits have significantly improved. From January to August, the batch issuance data for vaccines saw a substantial year-on-year increase, with pet vaccines such as rabies vaccine and feline trivalent vaccine growing by 16.8% and 78.9%, respectively. The prices of veterinary raw materials rebounded since late August, with the VPI index rising by approximately 2.1%. The tightening of supply and increased demand have driven price increases, particularly benefiting products like florfenicol as market competition eases

Huachuang Securities: In August, the growth of vaccines for diarrhea, brucellosis, and feline trivalent was strong, and the raw materials for veterinary drugs are entering a peak season with price increases

In August-September 2024, PULIKE Biotechnology Co., Ltd. plans to conduct cash management for temporarily idle raised funds not exceeding 265 million yuan, subject to review and approval. The usage period will be valid for 12 months from the date of approval at the third extraordinary general meeting of shareholders in 2024. On August 22, 2025, the company will fully redeem the idle raised funds under cash management and return them to the designated account

PULIKE: 265 million idle fundraising cash management matures, recovering principal of 821 million with earnings of 3.6653 million

688098

002688

Guohai Securities released a research report indicating that the domestic animal health industry is undergoing structural adjustments, with sales growth slowing to 3.7% from 2020 to 2023, and gross profit declining by 3.2%. As pet health awareness increases, pet medical care and overseas expansion will become new growth points. Leading companies are expected to gain larger market shares due to their rich product offerings and investment in research and development. Competition within the industry is intensifying, with frequent price wars, putting pressure on small and medium-sized enterprises

Shen Lian Biomedical

Jinhe Biotechnology

Guohai Securities: The "Matthew Effect" in the animal protection industry intensifies, and pet pharmaceuticals and overseas expansion are expected to open up medium to long-term growth space

PULIKE expects that the net profit attributable to the parent company in the first half of 2025 will increase by 44.70% to 64.98% year-on-year, reaching between 107 million and 122 million yuan. The launch of new products such as the live vaccine for pseudorabies in pigs and the adenovirus series five-in-one vaccine for poultry has driven performance growth, and sales of pet-related products continue to grow rapidly. The company optimizes costs and strengthens sales expense control through marketing system reform and lean production management to ensure the achievement of sales targets

PULIKE issued a profit forecast, expecting a year-on-year increase of 44.70% to 64.98% in net profit attributable to the parent company in the first half of the year

PULIKE's wholly-owned subsidiary Luoyang Huizhong Biotechnology Co., Ltd. has obtained a new veterinary drug registration certificate, approving a vaccine that can prevent Newcastle disease, infectious bronchitis, infectious bursal disease, and viral arthritis in chickens. This vaccine has advantages such as a long immune protection period, rapid antibody production, and high antibody titers, aimed at reducing losses in the poultry farming industry

PULIKE's subsidiary has obtained a new veterinary drug registration certificate

PULIKE announced that the "Fluralaner Solution" jointly applied for by the company and its wholly-owned subsidiary Luoyang Huizhong Veterinary Medicine Co., Ltd. has obtained a new veterinary drug registration certificate issued by the Ministry of Agriculture and Rural Affairs. This new veterinary drug is used to treat chicken skin mites in replacement chickens, laying hens, and breeding chickens. The acquisition of the new veterinary drug certificate is a result of the company's continuous emphasis on technological innovation and increased investment in research and development, which positively promotes the company's product market competitiveness and drives performance growth in the chemical drug sector

PULIKE: Obtained a new veterinary drug registration certificate

PULIKE(603566.SH)